Market Closed -
Nasdaq
01:30:00 27/04/2024 am IST
|
5-day change
|
1st Jan Change
|
64.06
USD
|
+2.23%
|
|
+3.12%
|
-16.98%
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,896
|
10,094
|
17,511
|
13,600
|
12,852
|
10,070
|
-
|
-
|
Enterprise Value (EV)
1 |
8,235
|
10,179
|
17,621
|
13,609
|
12,997
|
10,256
|
10,059
|
9,708
|
P/E ratio
|
84.4
x
|
45.4
x
|
130
x
|
52.3
x
|
46.4
x
|
57.7
x
|
45.1
x
|
38.3
x
|
Yield
|
0.61%
|
0.48%
|
0.28%
|
0.37%
|
-
|
0.5%
|
0.5%
|
0.52%
|
Capitalization / Revenue
|
11.1
x
|
13.7
x
|
18.8
x
|
12.3
x
|
11.3
x
|
8.78
x
|
8.09
x
|
7.3
x
|
EV / Revenue
|
11.5
x
|
13.8
x
|
18.9
x
|
12.3
x
|
11.4
x
|
8.95
x
|
8.08
x
|
7.04
x
|
EV / EBITDA
|
31.2
x
|
38
x
|
45.7
x
|
30.3
x
|
29.5
x
|
25.5
x
|
22
x
|
18.8
x
|
EV / FCF
|
52.7
x
|
66.4
x
|
57.2
x
|
48.5
x
|
60.1
x
|
39
x
|
30.3
x
|
27.8
x
|
FCF Yield
|
1.9%
|
1.51%
|
1.75%
|
2.06%
|
1.66%
|
2.57%
|
3.3%
|
3.6%
|
Price to Book
|
6.96
x
|
7.53
x
|
11.2
x
|
8.36
x
|
6.72
x
|
4.88
x
|
4.36
x
|
3.87
x
|
Nbr of stocks (in thousands)
|
1,51,491
|
1,52,892
|
1,55,567
|
1,56,934
|
1,57,437
|
1,57,192
|
-
|
-
|
Reference price
2 |
52.12
|
66.02
|
112.6
|
86.66
|
81.63
|
64.06
|
64.06
|
64.06
|
Announcement Date
|
06/08/19
|
04/08/20
|
05/08/21
|
04/08/22
|
08/08/23
|
-
|
-
|
-
|
Fiscal Period: Juni |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
714
|
738.7
|
931
|
1,106
|
1,137
|
1,146
|
1,245
|
1,380
|
EBITDA
1 |
264.3
|
268.1
|
385.7
|
449.3
|
441
|
401.5
|
456.7
|
516.9
|
EBIT
1 |
244.7
|
246.3
|
362.2
|
421.3
|
410.2
|
367.1
|
422
|
475.1
|
Operating Margin
|
34.27%
|
33.34%
|
38.9%
|
38.11%
|
36.09%
|
32.02%
|
33.9%
|
34.44%
|
Earnings before Tax (EBT)
1 |
112
|
276.5
|
148.2
|
301.4
|
338.7
|
201.8
|
272.8
|
332.2
|
Net income
1 |
96.07
|
229.3
|
140.4
|
272.1
|
285.3
|
178.8
|
228.5
|
267.6
|
Net margin
|
13.46%
|
31.04%
|
15.08%
|
24.61%
|
25.1%
|
15.6%
|
18.36%
|
19.39%
|
EPS
2 |
0.6175
|
1.455
|
0.8675
|
1.658
|
1.760
|
1.110
|
1.420
|
1.672
|
Free Cash Flow
1 |
156.2
|
153.2
|
307.9
|
280.4
|
216.1
|
263.2
|
331.9
|
349.1
|
FCF margin
|
21.88%
|
20.75%
|
33.07%
|
25.36%
|
19.02%
|
22.96%
|
26.66%
|
25.31%
|
FCF Conversion (EBITDA)
|
59.09%
|
57.15%
|
79.82%
|
62.4%
|
49.01%
|
65.55%
|
72.68%
|
67.54%
|
FCF Conversion (Net income)
|
162.59%
|
66.83%
|
219.26%
|
103.06%
|
75.77%
|
147.19%
|
145.23%
|
130.49%
|
Dividend per Share
2 |
0.3200
|
0.3200
|
0.3200
|
0.3200
|
-
|
0.3200
|
0.3200
|
0.3333
|
Announcement Date
|
06/08/19
|
04/08/20
|
05/08/21
|
04/08/22
|
08/08/23
|
-
|
-
|
-
|
Fiscal Period: June |
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
---|
Net sales
1 |
257.7
|
269.3
|
290.4
|
288.2
|
269.7
|
271.6
|
294.1
|
301.3
|
276.9
|
272.6
|
292.8
|
304.6
|
291.5
|
297
|
320
|
EBITDA
1 |
103.7
|
109.5
|
121.8
|
114.3
|
100.5
|
104
|
116.4
|
120
|
95.58
|
93.23
|
103.4
|
112.7
|
103.4
|
106.3
|
119.5
|
EBIT
1 |
97.35
|
102.8
|
114.6
|
106.6
|
93.18
|
96.47
|
108.7
|
111.8
|
86.89
|
81.94
|
94.38
|
103.3
|
94.61
|
97.65
|
110.3
|
Operating Margin
|
37.77%
|
38.19%
|
39.45%
|
36.97%
|
34.55%
|
35.52%
|
36.96%
|
37.12%
|
31.38%
|
30.06%
|
32.24%
|
33.92%
|
32.45%
|
32.87%
|
34.48%
|
Earnings before Tax (EBT)
1 |
67.38
|
86.18
|
68.77
|
79.05
|
103.7
|
66.43
|
80.2
|
88.32
|
49.56
|
33.39
|
56
|
63.42
|
56.68
|
62.65
|
74.72
|
Net income
1 |
69.62
|
80.17
|
60.74
|
61.52
|
89.56
|
50
|
70.22
|
75.48
|
50.99
|
27.46
|
46.7
|
54.04
|
47.19
|
52.15
|
61.29
|
Net margin
|
27.01%
|
29.77%
|
20.92%
|
21.35%
|
33.21%
|
18.41%
|
23.87%
|
25.05%
|
18.41%
|
10.08%
|
15.95%
|
17.74%
|
16.19%
|
17.56%
|
19.15%
|
EPS
2 |
0.4225
|
0.4850
|
0.3700
|
0.3775
|
0.5525
|
0.3100
|
0.4300
|
0.4700
|
0.3100
|
0.1700
|
0.2880
|
0.3380
|
0.3000
|
0.3250
|
0.3850
|
Dividend per Share
2 |
0.0800
|
0.0800
|
0.0800
|
0.0800
|
0.0800
|
0.0800
|
0.0800
|
-
|
0.0800
|
-
|
0.0800
|
0.0800
|
0.0800
|
0.0800
|
0.0800
|
Announcement Date
|
02/11/21
|
01/02/22
|
04/05/22
|
04/08/22
|
01/11/22
|
02/02/23
|
03/05/23
|
08/08/23
|
31/10/23
|
01/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
339
|
85.9
|
110
|
8.88
|
146
|
187
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
10.8
|
362
|
Leverage (Debt/EBITDA)
|
1.283
x
|
0.3202
x
|
0.2846
x
|
0.0198
x
|
0.3304
x
|
0.4652
x
|
-
|
-
|
Free Cash Flow
1 |
156
|
153
|
308
|
280
|
216
|
263
|
332
|
349
|
ROE (net income / shareholders' equity)
|
15.6%
|
14.1%
|
9.51%
|
16.6%
|
17.5%
|
14.3%
|
14.7%
|
15%
|
ROA (Net income/ Total Assets)
|
10.1%
|
9.17%
|
6.55%
|
11.9%
|
13%
|
11.3%
|
12%
|
12.7%
|
Assets
1 |
952.1
|
2,501
|
2,145
|
2,279
|
2,189
|
1,588
|
1,910
|
2,105
|
Book Value Per Share
2 |
7.490
|
8.760
|
10.00
|
10.40
|
12.10
|
13.10
|
14.70
|
16.50
|
Cash Flow per Share
2 |
1.170
|
1.300
|
2.170
|
1.980
|
1.570
|
2.000
|
2.230
|
2.510
|
Capex
1 |
25.4
|
51.7
|
44.3
|
44.9
|
38.2
|
53
|
56
|
57.9
|
Capex / Sales
|
3.56%
|
7%
|
4.76%
|
4.06%
|
3.36%
|
4.63%
|
4.5%
|
4.2%
|
Announcement Date
|
06/08/19
|
04/08/20
|
05/08/21
|
04/08/22
|
08/08/23
|
-
|
-
|
-
|
Last Close Price
64.06
USD Average target price
80.43
USD Spread / Average Target +25.56% Consensus |
1st Jan change
|
Capi.
|
---|
| -16.98% | 10.07B | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|